Charles Moore,  —

The first nanotechnology-enabled gene delivery system capable of efficiently penetrating the hard-to-breach mucus barrier shielding human airway and lung tissue may have been discovered with potential to one day develop an inhaled vehicle for delivery of targeted therapeutic genes that may be delivered directly to the lungs at levels sufficient…

The U.S. Food and Drug Administration on Thursday, July 2 announced that it has approved the first cystic fibrosis treatment that targets the cause of the disease. Orkambi is an oral ivacaftor/lumacaftor combination medication for treatment of CF that targets the underlying cause of the disease in people who have…

Jason van’t Slot — a 20-year-old South African — was born with Cystic Fibrosis, and after receiving a prognosis of a 10-year life span at the age of 8 months, celebrated his 20th year of living with CF by cycling the beguiling and grueling ABSA Cape Epic — the toughest…

Garden Grove, California based Novoteris, LLC has received $2.8 million in funding from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) to develop an inhaled nitric oxide antimicrobial therapy for people with cystic fibrosis (CF) who have airway bacterial colonization. CFFT is the nonprofit drug discovery and development affiliate of the Cystic…

Boulder, Colorado based Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), recently announced its initial public offering (IPO) which included 5.5 million shares of common stock priced at $14.00 per share before underwriting discounts and commissions. Nivalis additionally granted underwriters a 30-day option…

The five-year survival rate for Canadians with cystic fibrosis who have received a lung transplant is 67% and half of those who have had transplants live beyond 10 years, new research has found. The encouraging statistics were published today in the Journal of Heart Lung Transplantation by…

Internationally recognized Cystic Fibrosis expert and State University of New York at Buffalo clinical professor of pediatrics Drucy S. Borowitz, MD has received the 2015 Stockton Kimball Award for outstanding scientific achievement and service She accepted the honor at a May 28 SUNY Buffalo School of Medicine and…

The lead drug candidate under development by Celtaxsys — an Atlanta, Georgia based clinical-stage development company focused on novel therapeutics for treating inflammatory disease through regulation of immune cell migration and activation — is CTX-4430, described as a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor that shows promise as…

The U.K. based Cystic Fibrosis Trust, a national charity that funds research into the disease and provides information and support for patients and families, has announced that the nonprofit organization will standardize using DocuSign for Digital Transaction Management in order to eliminate printing, faxing, scanning and overnighting documents in…

Dr. Ewa Goldys and research colleagues at the Centre for Nanoscale BioPhotonics (CNBP) at Macquarie University in Sydney have published a research paper in the open access journal Sensors, claiming that diseases such as cystic fibrosis, acute pancreatitis and rheumatoid arthritis can be diagnosed…